As AstraZeneca prepares to submit its COVID-19 vaccine for U.S. authorization, reports of blood clots in several recipients have prompted several European countries to suspend its use. The World Health Organization has said the vaccine is not linked to increased risk for blood clots; a European agency is investigating.